Taipao's pioneering technology can greatly increase the yield of stem cells

[Rina123RS]

Yang Junyao pointed out that including cell survival rate, cell purity, cell functionality and other indicators, Taibao can lead the industry. "The overall yield is more than doubled. , I told the founding team to develop into a mass production platform (CDMO).”

But if you want to be a CDMO, the most important thing is to find customers. At that time, the demand for cell production extended by the Special Control Law emerged. Taibao, which owns a GMP cell production plant, first looked for customers from Taiwan.

In addition, Yang Junyao also began to think about ways to "add value" to the platform. In 2021, he approached the University of California, Davis. "The University of California increases cell function through genetic modification." Yang Junyao thinks that by using Taibao's high-yield CDMO service to further improve cell functionality, "the effect of cell drugs will be enhanced."

With continued recognition from customers in its cell-based CDMO, Taibao, which in the past mainly focused on cutting-edge advanced biotech medicine, Aiwanlin Biotechnology and other Taiwanese customers, began india telegram to attract international customers last year. In 2022, a Swiss pharmaceutical company came to Taiwan for pre-clinical preparations and approached Taibao for local OEM production.

"He originally came to the French CDMO factory to improve the process from a few hundred milliliters to 1 liter, but the result was stuck." Yang Junyao recalled that at that time, the customer turned to Taibao and asked Taibao for process improvement. In the end, Taibao spent three months to make the process. When it comes to the 5-liter mass production process, "the goal is to reach 20 liters." He said that with the expansion of clinical scale in the future and even production after certification, Taibao will continue to expand production capacity for customers.

CDMO has also become the key to Taibao's cooperation with Harvard. Yang Junyao pointed out that at that time, Taibao was competing with teams from China and Japan. What Harvard cared about most was "finding plans for the product to enter clinical practice as quickly as possible." Taibao had already prepared a CDMO production line. , with the advantages of ensuring production capacity in the clinical stage and adjusting the characteristics of cell drugs, Taibao defeated its competitors and gained the trust of Harvard in eight months.